Does DPP-IV Inhibition Offer New Avenues for Therapeutic Intervention in Malignant Disease?
Does DPP-IV Inhibition Offer New Avenues for Therapeutic Intervention in Malignant Disease?
About this item
Full title
Author / Creator
Publisher
Switzerland: MDPI AG
Journal title
Language
English
Formats
Publication information
Publisher
Switzerland: MDPI AG
Subjects
More information
Scope and Contents
Contents
Dipeptidyl peptidase IV (DPP-IV, CD26) is frequently dysregulated in cancer and plays an important role in regulating multiple bioactive peptides with the potential to influence cancer progression and the recruitment of immune cells. Therefore, it represents a potential contributing factor to cancer pathogenesis and an attractive therapeutic target...
Alternative Titles
Full title
Does DPP-IV Inhibition Offer New Avenues for Therapeutic Intervention in Malignant Disease?
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9103952
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9103952
Other Identifiers
ISSN
2072-6694
E-ISSN
2072-6694
DOI
10.3390/cancers14092072
